- Home
- AIFF vs PULM Comparison
AIFF vs PULM Comparison
Compare AIFF & PULM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AIFF
- PULM
- Stock Information
- Founded
- AIFF 2006
- PULM 2003
- Country
- AIFF United States
- PULM United States
- Employees
- AIFF N/A
- PULM N/A
- Industry
- AIFF
- PULM Biotechnology: Pharmaceutical Preparations
- Sector
- AIFF
- PULM Health Care
- Exchange
- AIFF NYSE
- PULM Nasdaq
- Market Cap
- AIFF 37.9M
- PULM 33.2M
- IPO Year
- AIFF N/A
- PULM N/A
- Fundamental
- Price
- AIFF $3.03
- PULM $6.53
- Analyst Decision
- AIFF
- PULM
- Analyst Count
- AIFF 0
- PULM 0
- Target Price
- AIFF N/A
- PULM N/A
- AVG Volume (30 Days)
- AIFF 1.6M
- PULM 63.0K
- Earning Date
- AIFF 08-18-2025
- PULM 08-12-2025
- Dividend Yield
- AIFF N/A
- PULM N/A
- EPS Growth
- AIFF N/A
- PULM N/A
- EPS
- AIFF N/A
- PULM N/A
- Revenue
- AIFF $139,000.00
- PULM $1,921,000.00
- Revenue This Year
- AIFF N/A
- PULM N/A
- Revenue Next Year
- AIFF N/A
- PULM $134.88
- P/E Ratio
- AIFF N/A
- PULM N/A
- Revenue Growth
- AIFF N/A
- PULM N/A
- 52 Week Low
- AIFF $1.86
- PULM $1.78
- 52 Week High
- AIFF $17.20
- PULM $10.40
- Technical
- Relative Strength Index (RSI)
- AIFF 55.14
- PULM 41.09
- Support Level
- AIFF $2.70
- PULM $6.51
- Resistance Level
- AIFF $3.09
- PULM $7.00
- Average True Range (ATR)
- AIFF 0.25
- PULM 0.89
- MACD
- AIFF 0.03
- PULM -0.16
- Stochastic Oscillator
- AIFF 47.74
- PULM 44.16
About AIFF FIREFLY NEUROSCIENCE INC
Firefly Neuroscience Inc is an AI company developing neuroscientific solutions that improve outcomes for patients with mental illnesses and cognitive disorders. It is focused on the commercialization of its Brain Network Analytics (BNA) software platform (the "BNA Platform")and the discovery and clinical development of biomarkers that support outcomes for people suffering from mental illnesses and cognitive disorders. The Company has one reportable segment: the BNA platform. The Company derives revenue from North America.
About PULM Pulmatrix Inc.
Pulmatrix Inc is a biopharmaceutical company that has focused on the development of novel inhaled therapeutic products intended to prevent and treat migraine and respiratory diseases with important unmet medical needs using its patented dry powder delivery technology, iSPERSE. Its pipeline of clinical assets includes PUR3100 for the treatment of acute migraine, PUR1800 for the treatment of acute exacerbations of chronic obstructive pulmonary disease (AECOPD), and PUR1900 for the treatment of ABPA in patients with asthma and in patients with cystic fibrosis (CF).